Search

Your search keyword '"von Eynatten, Maximilian"' showing total 397 results
Start Over Author "von Eynatten, Maximilian"
397 results on '"von Eynatten, Maximilian"'

3. Change in Albuminuria and GFR Slope as Joint Surrogate End Points for Kidney Failure: Implications for Phase 2 Clinical Trials in CKD

Author

Heerspink, Hiddo J.L., Inker, Lesley A., Tighiouart, Hocine, Collier, Willem H., Haaland, Benjamin, Luo, Jiyu, Appel, Gerald B., Chan, Tak Mao, Estacio, Raymond O., Fervenza, Fernando, Floege, Jürgen, Imai, Enyu, Jafar, Tazeen H., Lewis, Julia B., Kam-Tao Li, Philip, Locatelli, Francesco, Maes, Bart D., Perna, Annalisa, Perrone, Ronald D., Praga, Manuel, Schena, Francesco P., Wanner, Christoph, Xie, Di, Greene, Tom, Schrier, Robert W., Hanratty, Rebecca, Maschio, Giuseppe, Carlo, Manno, Saddelli, Mauro, Brenner, Barry M., Lewis, Edmund, von Eynatten, Maximilian, de Jong, Paul E., van Essen, GG, Hou, Fan Fan, Chapman, Arlene, Torres, Vicente, Yu, Alan, Brosnahan, Godela, Chow, Kai-Ming, Szeto, Cheuk-Chun, Leung, Chi-Bon, Hunsicker, Lawrence G., Dwyer, Jamie, Pohl, Marc, Raz, Itamar, Del Vecchio, Lucia, Andrulli, Simeone, Pozzi, Claudio, Casartelli, Donatella, Malfait, Thomas, Vanacker, An, Caravaca-Fontán, Fernando, Trujillo, Hernando, Cavero, Teresa, Gutierrez, Eduardo, Beck, Gerald, Kusek, John, Eknoyan, Garabed, Ponticelli, Claudio, Montagnino, Giuseppe, Passerini, Patrizia, Moroni, Gabriella, Kobayashi, Fumiaki, Makino, Hirofumi, Ito, Sadayoshi, Chan, Juliana CN, Tang, Colin, Gaspari, Flavio, Lesti, Maria Domenica, Gherardi, Giulia, Gamba, Sara, Keane, William, Donadio, James, Rauen, Thomas, Seikrit, Claudia, Wied, Stefanie, Dwyer, Jamie, and Becker, Gavin J.

Published
2023
Full Text
View/download PDF

4. Oligomalt, a New Slowly Digestible Carbohydrate, Reduces Post-Prandial Glucose and Insulin Trajectories Compared to Maltodextrin across Different Population Characteristics: Double-Blind Randomized Controlled Trials in Healthy Individuals, People with Obesity, and People with Type 2 Diabetes

Author

Johansen, Odd Erik, Neutel, Joel, Gupta, Sanjay, Mariani, Barbara, Ufheil, Gerhard, Perrin, Emilie, Rytz, Andreas, Lahiry, Anirban, Delodder, Frederik, Lerea-Antes, Jaclyn, Ocampo, Naomi, and von Eynatten, Maximilian

Subjects
TYPE 2 diabetes, DIETARY carbohydrates, RANDOMIZED controlled trials, BREATH tests, CARBOHYDRATES, MALTODEXTRIN
Abstract

We assessed the glucometabolic effects of oligomalt, a novel fully slowly digestible carbohydrate, compared with maltodextrin, in cross-over randomized controlled trials (NCT05058144; NCT05963594) involving healthy volunteers (HV), people with overweight or obesity (PwO), and people with type 2 diabetes (T2D). We tested 33 g and/or 50 g of oligomalt/maltodextrin, which were dissolved in 300 mL of water and consumed after fasting in the morning. The primary exploratory endpoint was the incremental area under the curve (iAUC) for postprandial glucose, assessed by frequent blood sampling over 3 h. Insulin levels were also assessed. In the HV cohort, a 4 h hydrogen breath test was performed with 15 g of inulin as a positive control. Analysis was performed by a mixed model. Oligomalt elicited a lower post-prandial glucose response compared to maltodextrin in HV (50 g, n = 15 [7 women], mean age/BMI 31 years/22.6 kg/m2), in PwO (33 g and 50 g, n = 26 [10 women], age/BMI 44 years/29.9 kg/m2, mean HbA1c 5.3%), and in people with T2D (50 g, n = 22 [13 women], age/BMI 61 years/31.8 kg/m2, HbA1c 7.4%), with significant reductions observed in PwO and T2D for the 0–1 h window (HV: −19% [p = 0.149]/PwO33g-38% [p = 0.0002]/PwO50g-28% [p = 0.0027]/T2D-38% [p < 0.0001]; the 0–2 h window (HV: −17% [p = 0.311]/PwO33g-34% [p = 0.0057]/PwO50g-21% [p = 0.0415]/T2D-37% [p < 0.0001]), and the 0–3 h window (HV: −15% [p = 0.386]/PwO33g-30% [p = 0.0213]/PwO50g0−19% [p = 0.0686]/T2D−37% [p = 0.0001]). The post-prandial insulin response was significantly lower, by 38–60%, across all populations, dose, and time points, with oligomalt. In HV, the breath-hydrogen pattern was comparable between oligomalt and maltodextrin, but increased significantly with inulin. These data support the glucometabolic advantages of oligomalt over maltodextrin, hence confirming it as a healthier carbohydrate, and underscoring its full digestibility. This therefore opens up the possibility for the incorporation of oligomalt in relevant food products/matrices. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial

Author

Kraus, Bettina J., Weir, Matthew R., Bakris, George L., Mattheus, Michaela, Cherney, David Z.I., Sattar, Naveed, Heerspink, Hiddo J.L., Ritter, Ivana, von Eynatten, Maximilian, Zinman, Bernard, Inzucchi, Silvio E., Wanner, Christoph, and Koitka-Weber, Audrey

Published
2021
Full Text
View/download PDF

7. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial

Author

McGuire, Darren K, Zinman, Bernard, Inzucchi, Silvio E, Wanner, Christoph, Fitchett, David, Anker, Stefan D, Pocock, Stuart, Kaspers, Stefan, George, Jyothis T, von Eynatten, Maximilian, Johansen, Odd Erik, Jamal, Waheed, Mattheus, Michaela, Elsasser, Ulrich, Hantel, Stefan, and Lund, Søren S

Published
2020
Full Text
View/download PDF

8. Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial

Author

Inagaki, Nobuya, Yang, Wenying, Watada, Hirotaka, Ji, Linong, Schnaidt, Sven, Pfarr, Egon, Okamura, Tomoo, Johansen, Odd Erik, George, Jyothis T., von Eynatten, Maximilian, Rosenstock, Julio, Perkovic, Vlado, Wanner, Christoph, Cooper, Mark E., Alexander, John H., Komuro, Issei, and Nangaku, Masaomi

Published
2020
Full Text
View/download PDF

9. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials

Author

Sevillano, Angel, Kamper, Anne-Lise, van Zuilen, Arjan D., Brenner, Barry M., Maes, Bart, Ihle, Benno U., Barret, Brendan, Leung, CB, Szeto, CC, Fitzner, Christina, Wanner, Christoph, Pozzi, Claudio, Montagnino, Claudio Ponticelli, Xie, Di, de Zeeuw, Dick, Lewis, Edmund, Verde, Eduardo, Gutierrez, Eduardo, Imai, Enyu, Hou, Fan Fan, Caravaca, Fernando, Fervenza, Fernando C., Locatelli, Francesco, Schena, Francesco Paolo, Kobayashi, Fumiaki, Moroni, Gabriella, Becker, Gavin J., Beck, Gerald J., Appel, Gerald B., Frisch, Gershon, van Essen, GG, Maschio, Giuseppe, Remuzzi, Giuseppe, Montogrino, Giuseppe, Parving, Hans-Henrik, Heerspink, Hiddo J.L., Makino, Hirofumi, Jehan, Imitiaz, Wetzels, Jack F.M., Donadio, James, Dwyer, Jamie, van den Brand, Jan, Kusek, John, Lachin, John M., Luño, Jose, Lewis, Julia B., Floege, Jürgen, Abebe, Kaleab Z., Chow, KM, Hunsicker, Lawrence G., del Vecchio, Lucia, Carlo, Manno, Praga, Manuel, Goicoechea, Marian, von Eynatten, Maximilian, Poulter, Neil, Chaturvedi, Nish, Passerini, Patrizia, de Jong, Paul E., Blankestijn, Peter J., Li, Philip, Ruggenenti, Piero, Zucchelli, Pietro, Kincaid-Smith, Priscilla S., Hilgers, Ralf-Dieter, Estacio, Raymond O., Rohde, Richard D., Katafuchi, Ritsuko, Toto, Robert D., Schrier, Robert W., Rodby, Roger A., Perrone, Ronald D., Ito, Sadayoshi, Klahr, Saulo, Andrulli, Simeone, Strandgaard, Svend, Chan, Tak Mao, Hannedouche, Thierry P., Rauen, Thomas, Greene, Tom, Verdalles, Ursula, Perkovic, Vlado, Keane, William, Heerspink, Hiddo J L, Tighiouart, Hocine, Gansevoort, Ron T, Coresh, Josef, Simon, Andrew L, Lewis, Julia B, Levey, Andrew S, and Inker, Lesley A

Published
2019
Full Text
View/download PDF

11. A Mechanism Converting Psychosocial Stress into Mononuclear Cell Activation

Author

Bierhaus, Angelika, Wolf, Jutta, Andrassy, Martin, Rohleder, Nicolas, Humpert, Per M., Petrov, Dimitri, Ferstl, Roman, von Eynatten, Maximilian, Wendt, Thoralf, Rudofsky, Gottfried, Joswig, Martina, Morcos, Michael, Schwaninger, Markus, McEwen, Bruce, Kirschbaum, Clemens, and Nawroth, Peter P.

Published
2003

16. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA

Author

McGuire, Darren K., Alexander, John H., Johansen, Odd Erik, Perkovic, Vlado, Rosenstock, Julio, Cooper, Mark E., Wanner, Christoph, Kahn, Steven E., Toto, Robert D., Zinman, Bernard, Baanstra, David, Pfarr, Egon, Schnaidt, Sven, Meinicke, Thomas, George, Jyothis T., von Eynatten, Maximilian, and Marx, Nikolaus

Published
2019
Full Text
View/download PDF

22. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA‐T2D trial

Author

Groop, Per‐Henrik, Cooper, Mark E., Perkovic, Vlado, Hocher, Berthold, Kanasaki, Keizo, Haneda, Masakazu, Schernthaner, Guntram, Sharma, Kumar, Stanton, Robert C., Toto, Robert, Cescutti, Jessica, Gordat, Maud, Meinicke, Thomas, Koitka‐Weber, Audrey, Thiemann, Sandra, and von Eynatten, Maximilian

Published
2017
Full Text
View/download PDF

23. Oligomalt, a New Slowly Digestible Carbohydrate, Is Well Tolerated in Healthy Young Men and Women at Intakes Up to 180 Gram per Day: A Randomized, Double-Blind, Crossover Trial.

Author

Johansen, Odd Erik, Curti, Delphine, von Eynatten, Maximilian, Rytz, Andreas, Lahiry, Anirban, Delodder, Frederik, Ufheil, Gerhard, D'Urzo, Carmine, Orengo, Audrey, Thorne, Kate, and Lerea-Antes, Jaclyn S.

Abstract

In this randomized, double-blind triple-crossover study (NCT05142137), the digestive tolerance and safety of a novel, slowly digestible carbohydrate (SDC), oligomalt, an α-1,3/α-1,6-glucan α-glucose-based polymer, was assessed in healthy adults over three separate 7-day periods, comparing a high dose of oligomalt (180 g/day) or a moderate dose of oligomalt (80 g/day in combination with 100 g maltodextrin/day) with maltodextrin (180 g/day), provided as four daily servings in 300 mL of water with a meal. Each period was followed by a one-week washout. A total of 24 subjects (15 females, age 34 years, BMI 22.2 kg/m2, fasting blood glucose 4.9 mmol/L) were recruited, of whom 22 completed the course. The effects on the primary endpoint (the Gastrointestinal Symptom Rating Score (GSRS)) showed a statistically significant dose dependency, albeit of limited clinical relevance, between a high dose of oligomalt and maltodextrin (mean (95% CI) 2.29 [2.04, 2.54] vs. 1.59 [1.34, 1.83], respectively; difference: [−1.01, −0.4], p < 0.0001), driven by the GSRS-subdomains "Indigestion" and "Abdominal pain". The GSRS difference ameliorated with product exposure, and the GSRS in those who received high-dose oligomalt as their third intervention period was similar to pre-intervention (mean ± standard deviation: 1.6 ± 0.4 and 1.4 ± 0.3, respectively). Oligomalt did not have a clinically meaningful impact on the Bristol Stool Scale, and it did not cause serious adverse events. These results support the use of oligomalt across various doses as an SDC in healthy, normal weight, young adults. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

24. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk

Author

Rosenstock, Julio, Perkovic, Vlado, Alexander, John H., Cooper, Mark E., Marx, Nikolaus, Pencina, Michael J., Toto, Robert D., Wanner, Christoph, Zinman, Bernard, Baanstra, David, Pfarr, Egon, Mattheus, Michaela, Broedl, Uli C., Woerle, Hans-Juergen, George, Jyothis T., von Eynatten, Maximilian, McGuire, Darren K., and CARMELINA® investigators

Published
2018
Full Text
View/download PDF

26. 41-LB: A Randomized, Placebo-Controlled Crossover Study to Evaluate the Effect of a Natural Powder Blend (Mulberry Leaf Extract [MLE], Vitamin D, Chromium, and Fiber) on Postprandial (PP) Metabolic Response in Type 2 Diabetes (T2D)

Author

MOHAMED, MAFAUZY, primary, ZAGURY, ROBERTO, additional, BHASKARAN, KALPANA, additional, NEUTEL, JOEL M., additional, MOHD YUSOF, BARAKATUN-NISAK, additional, MOONEY, LINDA, additional, PERRIN, EMILIE, additional, SMITH, ALEX D., additional, APRIKIAN, OLIVIER, additional, VON EYNATTEN, MAXIMILIAN, additional, and JOHANSEN, ODD ERIK, additional

Published
2022
Full Text
View/download PDF

31. A Randomized Controlled Clinical Trial in Healthy Older Adults to Determine Efficacy of Glycine and N-Acetylcysteine Supplementation on Glutathione Redox Status and Oxidative Damage

Author

Lizzo, Giulia, primary, Migliavacca, Eugenia, additional, Lamers, Daniela, additional, Frézal, Adrien, additional, Corthesy, John, additional, Vinyes-Parès, Gerard, additional, Bosco, Nabil, additional, Karagounis, Leonidas G., additional, Hövelmann, Ulrike, additional, Heise, Tim, additional, von Eynatten, Maximilian, additional, and Gut, Philipp, additional

Published
2022
Full Text
View/download PDF

38. Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial

Author

Wanner, Christoph, primary, Cooper, Mark E, additional, Johansen, Odd Erik, additional, Toto, Robert, additional, Rosenstock, Julio, additional, McGuire, Darren K, additional, Kahn, Steven E, additional, Pfarr, Egon, additional, Schnaidt, Sven, additional, von Eynatten, Maximilian, additional, George, Jyothis T, additional, Gollop, Nicholas D, additional, Marx, Nikolaus, additional, Alexander, John H, additional, Zinman, Bernard, additional, and Perkovic, Vlado, additional

Published
2021
Full Text
View/download PDF

39. Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial

Author

Wanner, Christoph, Cooper, Mark E., George, Jyothis T., Gollop, Nicholas D., Marx, Nikolaus, Alexander, John H., Zinman, Bernard, Perkovic, Vlado, CARMELINAinvestigators, Johansen, Odd Erik, Toto, Robert, Rosenstock, Julio, McGuire, Darren K., Kahn, Steven E., Pfarr, Egon, Schnaidt, Sven, and von Eynatten, Maximilian

Abstract

Clinical kidney journal 14(9), 2136-2136 (2021). doi:10.1093/ckj/sfab104, Published by Oxford Univ. Press, Oxford

Published
2021
Full Text
View/download PDF

41. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction

Author

Groop, Per-Henrik, Cooper, Mark E., Perkovic, Vlado, Emser, Angela, Woerle, Hans-Juergen, and von Eynatten, Maximilian

Subjects
Diabetes therapy -- Standards -- Analysis, Type 2 diabetes -- Analysis, Angiotensin -- Analysis, Health, European Association for the Study of Diabetes
Abstract

OBJECTIVE--Preclinical data suggest that linagliptin, a dipeptidyl peptidase-4 inhibitor, may lower urinary albumin excretion. The ability of linagliptin to lower albuminuria on top of renin-angiotensin-aldosterone system (RAAS) inhibition in humans [...]

Published
2013
Full Text
View/download PDF

49. LB005KIDNEY IMPLICATIONS OF THE INITIAL EGFR RESPONSE TO SGLT2 INHIBITION WITH EMPAGLIFLOZIN: THE ‘EGFR DIP’ IN EMPA-REG OUTCOME

Author

Kraus, Bettina J, primary, Weir, Matthew, primary, Bakris, George, primary, Mattheus, Michaela, primary, Cherney, David, primary, Sattar, Naveed, primary, Lambers Heerspink, Hiddo, primary, Ritter, Ivana, primary, Von Eynatten, Maximilian, primary, Zinman, Bernard, primary, Inzucchi, Silvio, primary, Wanner, Christoph, primary, and Koitka-Weber, Audrey, primary

Published
2020
Full Text
View/download PDF

50. The authors reply

Author

Mayer, Gert J., primary, Wanner, Christoph, additional, Weir, Matthew R., additional, Inzucchi, Silvio E., additional, Koitka-Weber, Audrey, additional, Hantel, Stefan, additional, von Eynatten, Maximilian, additional, Zinman, Bernard, additional, and Cherney, David Z.I., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results